PURPOSE: Obstructive jaundice (OJ) is a cumbersome complication in late-stage malignancies, and percutaneous transhepatic biliary drainage (PTBD) is often used to relieve symptoms and allow chemotherapy (CT). METHODS: From July 2008 to August 2011, 71 patients (pts) with OJ due to solid malignancies underwent PTBD in our institution. Baseline characteristics, procedure complications, and outcomes were retrospectively collected. The primary objective was to estimate overall survival (OS) after PTBD. RESULTS: Median age was 60 years, 63% had an ECOG performance status (PS) of 1-2, and 10% were receiving supportive care (SC). Most had primary gastrointestinal tumors (89%) and metastatic disease at diagnosis (59%). Mean hospital stay was 16.6 days (2-90 days), with bilirubin value decreased (BVD) after 80% of procedures. Cholangitis was observed in 66.2% of pts and 60.6% required readmissions. Only 51.6% of pts not in SC were eligible for CT after PTBD. Median OS was 2.9 months (95% CI 0.62-5.2). Prognostic factors on univariate analysis include ECOG ≤2 (6.8 versus 0.79 months, p < 0.0001), BVD (6.7 versus 0.33 months, p < 0.0001), and CT after PTBD (13.7 versus 1.2 months p < 0.0001). On multivariate analysis, CT after procedure was related to better OS (HR 0.15, CI 0.06-0.38, p < 0.001). CONCLUSIONS: Malignant OJ is a late event in cancer pts. Thorough evaluation is needed before determining eligibility to PTBD due to its high complication and hospitalization rates. In the current analysis, pts with PS >2 and who are not candidates for further CT had a dismal prognosis and should probably not be offered PTBD.
PURPOSE: Obstructive jaundice (OJ) is a cumbersome complication in late-stage malignancies, and percutaneous transhepatic biliary drainage (PTBD) is often used to relieve symptoms and allow chemotherapy (CT). METHODS: From July 2008 to August 2011, 71 patients (pts) with OJ due to solid malignancies underwent PTBD in our institution. Baseline characteristics, procedure complications, and outcomes were retrospectively collected. The primary objective was to estimate overall survival (OS) after PTBD. RESULTS: Median age was 60 years, 63% had an ECOG performance status (PS) of 1-2, and 10% were receiving supportive care (SC). Most had primary gastrointestinal tumors (89%) and metastatic disease at diagnosis (59%). Mean hospital stay was 16.6 days (2-90 days), with bilirubin value decreased (BVD) after 80% of procedures. Cholangitis was observed in 66.2% of pts and 60.6% required readmissions. Only 51.6% of pts not in SC were eligible for CT after PTBD. Median OS was 2.9 months (95% CI 0.62-5.2). Prognostic factors on univariate analysis include ECOG ≤2 (6.8 versus 0.79 months, p < 0.0001), BVD (6.7 versus 0.33 months, p < 0.0001), and CT after PTBD (13.7 versus 1.2 months p < 0.0001). On multivariate analysis, CT after procedure was related to better OS (HR 0.15, CI 0.06-0.38, p < 0.001). CONCLUSIONS: Malignant OJ is a late event in cancerpts. Thorough evaluation is needed before determining eligibility to PTBD due to its high complication and hospitalization rates. In the current analysis, pts with PS >2 and who are not candidates for further CT had a dismal prognosis and should probably not be offered PTBD.
Authors: Adrian A Indar; Dileep N Lobo; Andrew D Gilliam; Roger Gregson; Ian Davidson; Simon Whittaker; John Doran; Brian J Rowlands; Ian J Beckingham Journal: Eur J Gastroenterol Hepatol Date: 2003-08 Impact factor: 2.566
Authors: P C Robson; N Heffernan; M Gonen; R Thornton; L A Brody; R Holmes; K T Brown; A M Covey; D Fleischer; G I Getrajdman; W Jarnagin; C Sofocleous; L Blumgart; M D'Angelica Journal: Ann Surg Oncol Date: 2010-04-01 Impact factor: 5.344
Authors: Zilvinas Dambrauskas; Saulius Paskauskas; Paulius Lizdenis; Rimantas Uktveris; Andrius Pranculis; Rytis Stasys Kaupas; Giedrius Barauskas; Juozas Pundzius Journal: Medicina (Kaunas) Date: 2008 Impact factor: 2.430
Authors: Alessandro Rizzo; Angela Dalia Ricci; Giorgio Frega; Andrea Palloni; Stefania DE Lorenzo; Francesca Abbati; Veronica Mollica; Simona Tavolari; Mariacristina DI Marco; Giovanni Brandi Journal: In Vivo Date: 2020 Jul-Aug Impact factor: 2.155
Authors: Eun L Langman; Paul V Suhocki; Herbert I Hurwitz; Michael A Morse; Rebecca A Burbridge; Tony P Smith; Charles Y Kim Journal: J Gastrointest Oncol Date: 2016-12
Authors: Vanessa da Costa Miranda; Maria Ignez Braghiroli; Luiza Dib Batista Bugiato Faria; Sheila Aparecida Coelho Siqueira; Jorge Sabbaga; Paulo M Hoff; Rachel P Riechelmann Journal: J Gastrointest Cancer Date: 2014-03